Adcetris, or brentuximab vedotin, received FDA approval for use with chemotherapy in treatment-naive patients with stage III or IV classical Hodgkin lymphoma. The therapy combines an anti-C30 antibody with monomethyl auristatin E to target lymphoma cells.
FDA approves Adcetris for classical Hodgkin lymphoma
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.